Hypertriglyceridemia - Pipeline Insight, 2021

Publisher Name :
Date: 12-Oct-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Hypertriglyceridemia - Pipeline Insight, 2021," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Hypertriglyceridemia Understanding

Hypertriglyceridemia: Overview

Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the "good" cholesterol, HDL (high-density lipoprotein).

"Hypertriglyceridemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs

- ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

- MND-21: Mochida Pharmaceutical

MND-21, a therapeutic agent for hypertriglyceridemia which is being developed in collaboration with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. in China. Currently, it is in Phase III stage of clinical trial evaluation to treat Hypertriglyceridaemia.

Further product details are provided in the report……..

Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Hypertriglyceridemia

There are approx. 22+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Mochida Pharmaceutical.

- Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravenous

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights

- Hypertriglyceridemia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Hypertriglyceridemia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Hypertriglyceridemia drugs?

- How many Hypertriglyceridemia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Hypertriglyceridemia and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Arrowhead Pharmaceuticals

- Mochida Pharmaceutical

- Ionis Pharmaceuticals

- 89bio

- Regeneron Pharmaceuticals

- Acasti Pharma Inc.

- Staten Biotechnology BV

- NorthSea Therapeutics B.V.

- Afimmune

- Rivus Pharmaceuticals

- Novo Nordisk

- Viking Therapeutics

- Liminal BioSciences

- Matinas BioPharma

- Arbutus Biopharma

- Better Therapeutics

Key Products

- ARO-APOC3

- MND-21

- IONIS-APOCIII-LRx

- BIO89-100

- Evinacumab

- CaPre

- STT-5058

- NST-1024

- DS102

- AKCEA-APOCIII-LRx

- NST-4016

- BT-005

- HU 6

- TKM-HTG

- COR 003

- MAT-9001

- VK 1430

- PBI 4050

Hypertriglyceridemia - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Hypertriglyceridemia: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Hypertriglyceridemia - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
* Comparative Analysis
MND-21: Mochida Pharmaceutical
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
ARO-APOC3: Arrowhead Pharmaceuticals
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
ARGX 116: argenx
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
* Comparative Analysis
VK 1430: Viking Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
* Comparative Analysis
Hypertriglyceridemia Key Companies
Hypertriglyceridemia Key Products
Hypertriglyceridemia- Unmet Needs
Hypertriglyceridemia- Market Drivers and Barriers
Hypertriglyceridemia- Future Perspectives and Conclusion
Hypertriglyceridemia Analyst Views
Hypertriglyceridemia Key Companies
Appendix

List of Tables

Table 1 Total Products for Hypertriglyceridemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Hypertriglyceridemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • China Ocular Drug Delivery Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 91
    China Ocular Drug Delivery Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Type, 2020 (%) - Ocular Insert - Iontophoresis - Intraocular Implants - In Situ Gel & Punctal Plugs - Others China Ocular Drug Delivery Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Application, 2020 (%)......
  • China Nuclear Medicine/Radiopharmaceutic Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 93
    China Nuclear Medicine/Radiopharmaceutic Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment Percentages, By Type, 2020 (%) - Tc-99 - I-123/131 - In-111 - Xe-133 - Th-201 - Ga-67 - Other China Nuclear Medicine/Radiopharmaceutic Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment P......
  • China NSAIDs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China NSAIDs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Type, 2020 (%) - Aspirin - Ibuprofen - Naproxen - Nabumetone - Others China NSAIDs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Application, 2020 (%) - Back Pain Treatment - Osteoarthritis Treatment - Other Disease Treatment......
  • China Non-Tyrosine Kinase Inhibitors Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-Tyrosine Kinase Inhibitors Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Type, 2020 (%) - mTOR Inhibitors - RAF/MEK Inhibitors - CDK Inhibitors China Non-Tyrosine Kinase Inhibitors Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Application, 2020 (%) - Liver Can......
  • China Nonsteroidal Antiinflammatory Drugs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China Nonsteroidal Antiinflammatory Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percentages, By Type, 2020 (%) - Oral Nonsteroidal Antiinflammatory Drugs - Injection Nonsteroidal Antiinflammatory Drugs China Nonsteroidal Antiinflammatory Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percenta......
  • China Non-opioid Pain Patch Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-opioid Pain Patch Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Percentages, By Type, 2020 (%) - Lidocaine Patches - Diclofenac Patches - Indomethacin Patches - Counter-Irritant Patches - Fentanyl Patches - Others China Non-opioid Pain Patch Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Perc......
  • China Non Narcotic Analgesics Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 92
    China Non Narcotic Analgesics Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Type, 2020 (%) - Non Steroid Antiinflammatory Drug - Steroid Antiinflammatory Drug China Non Narcotic Analgesics Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Application, 2020 (%) - Hospital - Medical Center......
  • Global Azelastine Nasal Spray Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 100
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 0.137MG/SPRAY - 0.2055MG/SPRAY - Other Segment by Application - Hospital - Ret......
  • Global Azelastine Drug Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 114
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nasal Spray - Eye Drops - Other Segment by Application - Hospital - Retail Pha......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs